Why the study?
Does adding clopidogrel to aspirin reduce cardiovascular events in patients with acute coronary syndromes without ST-segment elevation myocardial infarction?
Does adding clopidogrel to aspirin reduce cardiovascular events in patients with acute coronary syndromes without ST-segment elevation myocardial infarction?
Answers are grounded in this paper and cite their sources.
Combination therapy with aspirin and clopidogrel is beneficial for patients with acute coronary syndromes without ST-segment elevation myocardial infarction, particularly those with aspirin resistance.
Platelet adhesion, activation, and aggregation are central to thrombus formation, which follows atherosclerotic plaque disruption and causes acute coronary syndromes. Aspirin and clopidogrel exert their antiplatelet effects by inhibiting thromboxane A2 production and adenosine diphosphate-induced platelet aggregation pathways, respectively. Aspirin has proven benefits in primary and secondary prevention of coronary artery disease. Clopidogrel, an alternative antiplatelet agent used in patients with aspirin intolerance, is especially useful in combination with aspirin after coronary stent procedures. The CURE (Clopidogrel in Unstable Angina to Prevent Recurrent Events) study demonstrates for the first time the benefit of adding clopidogrel to aspirin rather than using aspirin alone in patients having acute coronary syndromes without ST-segment elevation myocardial infarction. Patients who are resistant to aspirin (up to 10%) have higher rates of cardiovascular events and may derive special benefit from the combination therapy. Aspirin resistance can be assessed through platelet aggregometry testing, measurement of urinary thromboxane metabolites, and, possibly, genomic testing in the future.
No takes yet. Share an insight, caveat, or question.
Jneid et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: